home
About Us
home
Company Overview
Team Keynstone/Careers
Market Positioning
Core Business
home

CALECIM / SOLLAGEN

Skin Regeneration Solution ‘CALECIM’ Draws Attention with Clinical Results at Guangdong Hair Medicine Conference in China

Clear improvements in thickness and density for post-chemotherapy hair weakening cases Presented by Professor Kim Ji-seok of FUE ASIA, a hair transplant expert "CALECIM-RF" combination therapy shows higher satisfaction compared to existing procedures for post-chemo hair loss improvement
Professor Kim Ji-seok presenting CALECIM clinical results at the Guangdong Hair Medicine Conference in China. Provided by Keynstone.
Clinical results demonstrating that combining the secretome-based skin regeneration solution 'CALECIM' with Radio Frequency (RF) improves hair thickness and density—particularly in cases where hair has weakened following chemotherapy—were unveiled at the 'Guangdong Hair Medicine Conference' in Guangzhou, China, on August 30. The presentation garnered significant attention from cosmetic surgeons and medical experts worldwide.
On the 3rd, Keynstone, the exclusive distributor of CALECIM in Korea, reported that Professor Kim Ji-seok (Director of Mammoth Hairline Clinic) of FUE ASIA presented these findings, stating, "CALECIM tends to offer higher satisfaction and reduced discomfort during the procedure compared to existing PRP (Platelet-Rich Plasma) or stem cell-based treatments." He added, "Notably, improvements in thickness and density were observed in cases of hair weakening after chemotherapy."
Professor Kim, who was officially invited as the Korean representative speaker at the 'Guangdong Provincial Plastic and Aesthetic Association Hair & Scalp Health Management Branch Annual Meeting and the 1st Guangdong Hair Medicine Conference,' emphasized, "As a hair transplant expert who has conducted numerous clinical trials, I believe that transplantation alone is no longer sufficient. The synergistic effect of secretomes and high-frequency (RF) treatment improves the scalp environment and demonstrates new possibilities."
Skin Regeneration Solution ‘CALECIM’ Draws Attention with Clinical Results at Guangdong Hair Medicine Conference in China

US Billionaire Celebrity ‘Kim Kardashian’ Makes Surprise Visit to Korea… Buzz Surrounds Her Visit to Skin Regeneration Clinic

Kardashian sisters visit a Korean clinic famous for skin regeneration Procedure photos shared on Instagram to 350 million followers
Director Choi Jun-ho of Hoan Clinic performing a procedure using the skin regeneration solution ‘CALECIM Derma.’ Photo = Keynstone
It has recently become a hot topic that US billionaire and global celebrity Kim Kardashian and her sister made a surprise visit to Korea and stopped by ‘Hoan Clinic’ in Hannam-dong, Seoul.
Hoan Clinic, visited by the Kardashian sisters, is famous for its ‘Skin Regeneration Program’ jointly developed by ‘CellResearch’ and ‘Hoan Clinic.’ The clinic is gaining explosive popularity just one month after launching a combination of the skin regeneration solution ‘CALECIM Derma’ and the slow-aging program ‘Hoan Celix Package.’
Kim Kardashian shared photos of the procedure on her Instagram, which boasts 350 million followers. Additionally, US beauty expert Vanessa Lee, who accompanied Kim to Korea, posted a video of her Hoan Clinic experience on Instagram, spreading the word among influencers, fans, and beauty enthusiasts.
US Billionaire Celebrity ‘Kim Kardashian’ Makes Surprise Visit to Korea… Buzz Surrounds Her Visit to Skin Regeneration Clinic

‘Ms. Kim’ Kim Kardashian Falls for K-Beauty… Shares Photo from Hannam-dong Dermatology Clinic

The Kardashian sisters. Kim Kardashian's Instagram account
Global influencer and American TV personality Kim Kardashian and her sister visited a dermatology clinic in Seoul.
It has become a hot topic after it was revealed that the Kardashian sisters recently visited ‘Hoan Clinic’ in Hannam-dong, Seoul. Kim Kardashian personally shared a photo on her Instagram verifying that she received the clinic’s ‘Skin Regeneration Program.’
The program was jointly developed by the stem cell platform specialist ‘CellResearch’ and ‘Hoan Clinic.’ It combines the skin regeneration solution ‘CALECIM Derma’ with the slow-aging program ‘Hoan Celix Package.’
‘CALECIM Derma’ is a skin regeneration solution based on a bioactive protein complex independently developed by ‘CellResearch.’ It is currently being used in approximately 4,500 hospitals across 40 countries worldwide. It has recently garnered significant attention, with 1,000 hospitals applying to participate in clinical trials at a recent domestic conference.
‘Ms. Kim’ Kim Kardashian Falls for K-Beauty… Shares Photo from Hannam-dong Dermatology Clinic

CellResearch and Cheongdam U Plastic Surgery Center to Conduct Joint Clinical Trial for Hair Loss & Skin Regeneration Solution ‘CALECIM’

CALECIM to be applied to ‘CDU COMPLETE,’ a post-procedure recovery system Research Director Ivor Lim: "Korea is one of the countries with the most advanced plastic surgery technology."
Stem cell platform specialist 'CellResearch' announced on the 27th that it has officially signed a domestic joint clinical partnership agreement with Cheongdam U Plastic Surgery Center (CDU) for its hair loss and skin regeneration solution, 'CALECIM.'
'CALECIM' is a hair loss and skin regeneration solution based on the stem cell super-exosome 'PTT-6' developed by CellResearch. It garnered significant attention from dermatologists and plastic surgeons when first unveiled at the recently held '2025 Korean Academy of Laser, Dermatology and Trichology (KALDAT)' international conference. It became a hot topic when 1,000 domestic hospitals submitted letters of intent to participate in clinical trials within just three hours of applications opening to attending medical staff.
Together with 'Keynstone,' the exclusive supplier of CALECIM in Korea, CellResearch plans to fully support the CALECIM clinical trials at its Korean partner, CDU. The clinical results are planned to be presented at academic societies related to dermatology and plastic surgery and shared with approximately 4,500 CALECIM clinical partner hospitals worldwide.
CellResearch is a world-class stem cell platform company headquartered in Singapore. It has conducted research and development for over 20 years and possesses proprietary technology in the field of umbilical cord lining stem cells. Currently, its products have been introduced in over 4,500 hospitals and clinics across more than 40 countries—including the US, UK, Australia, and Hong Kong—for clinical and therapeutic use. The company is pursuing a NASDAQ listing, with an estimated corporate value of approximately 1 trillion KRW.
CellResearch and Cheongdam U Plastic Surgery Center to Conduct Joint Clinical Trial for Hair Loss & Skin Regeneration Solution ‘CALECIM’

CellResearch and Hoan Clinic Jointly Develop Slow-Aging Exosome Solution

CellResearch Corp announced on the 5th that it is partnering with 'Hoan Clinic' in Hannam-dong to develop a slow-aging solution that integrates its skin regeneration solution, 'CALECIM Derma,' with the 'Hoan Celix Package.'
'CALECIM Derma' is a skin regeneration solution based on the bioactive protein complex 'PTT-6 Secretome.' The company stated that PTT-6 Secretome is a refined complex of various bio-derived active substances—such as growth factors, cytokines, and exosomes—derived from umbilical cord lining stem cells, and it currently holds patents in 70 countries worldwide.
According to Hoan Clinic, CALECIM Derma has been integrated into the 'Hoan Celix Package.' The package consists of immune IV therapy, autologous stem cell skin boosters, and the topical application of CALECIM Derma. A key feature is that it induces continuous skin improvement effects in a non-irritating and non-invasive manner by utilizing CALECIM after prepping the skin condition.
Furthermore, CellResearch explained that Hoan Clinic’s sophisticated slow-aging care philosophy aligns with the direction CALECIM Derma aims for, and they expect to create a new skin regeneration system based on biological restorative power.
CellResearch and Hoan Clinic Jointly Develop Slow-Aging Exosome Solution

CellResearch Founder Ivor Lim: "Transcending Treatment Limits for Hair Loss, Diabetic Foot Ulcers, and Bedsores"

Targeting intractable skin diseases with ‘Super Exosomes’… The Challenge of CellResearch ‘PTT-6’ Goes Beyond Stem Cells: Inducing Regeneration with a Complex of 3,000 Components Following the US and Japan, Korea Opens Door to Cell Therapy… Full-scale Entry into the Domestic Market
Research Director Ivor Lim having an interview with Maeil Ilbo in Samseong-dong, Seoul. Photo = CellResearch
Singaporean biotech company ‘CellResearch’ is opening a new path for treating intractable skin diseases. Through next-generation stem cell technology dubbed ‘Super Exosomes,’ the company has demonstrated practical improvement possibilities for conditions difficult to recover from with existing treatments, such as diabetic foot ulcers, pressure ulcers (bedsores), and hair loss.
For diabetic patients, foot ulcers are a life-threatening agony. The fear that a single wound could lead to amputation dominates their daily lives. The same applies to bedsores (pressure ulcers) in patients with limited mobility. Even if not life-threatening, hair loss is a representative area of unmet medical need that drastically reduces quality of life.
CellResearch focused precisely on this point. The goal is to redefine exosome technology not just for external improvement, but as a platform to regeneratively treat diseases themselves. Maeil Ilbo met with Dr. Ivor J. Lim, the protagonist leading the technology development and Chief Scientific Officer (CSO) of CellResearch, to discuss the vision of ‘Super Exosome’ technology and business direction.
CellResearch Founder Ivor Lim: "Transcending Treatment Limits for Hair Loss, Diabetic Foot Ulcers, and Bedsores"

Hair Loss & Skin Regeneration Solution ‘CALECIM’ Clinical Campaign Closes in Just 3 Hours… 1,000 Hospitals Participate

Clinical campaign jointly promoted by CellResearch & Keynstone… Inquiries from hospitals for additional adoption pour in Super-exosome based solution… Proven increase in hair count & follicle cell proliferation, drawing attention for ‘Zero’ side effects Stem cell-based ‘CALECIM’ targets female hair loss & derma markets, signaling full-scale domestic expansion
Medical staff and hospital officials visiting the CALECIM clinical campaign booth at the Korean Academy of Laser, Dermatology and Trichology.
[Jungang Economy News, Yoon Nam-woong] The hair loss and skin regeneration solution 'CALECIM' attracted immense attention as its first joint clinical campaign with 1,000 domestic hospitals—aimed at 10 million hair loss sufferers and skin regeneration patients—reached its recruitment quota and closed early within just three hours.
On the 14th, the stem cell-based bio-specialist 'CellResearch' announced that following the launch of the clinical campaign to recruit 1,000 clinical hospitals for 'CALECIM' (Hair, Derma) targeting medical professionals at the '2025 Korean Academy of Laser, Dermatology and Trichology (KALDAT)' with its exclusive domestic distributor 'Keynstone,' applications were closed early, and inquiries regarding additional adoption are continuing to flow in.
Keynstone stated that 1,000 hospitals participating in the trial in just three hours is a highly exceptional achievement, signaling a successful launch in the domestic market. They plan to continuously expand joint clinical campaigns with hospitals wishing to participate as soon as sufficient volume is secured in the future.
Hair Loss & Skin Regeneration Solution ‘CALECIM’ Clinical Campaign Closes in Just 3 Hours… 1,000 Hospitals Participate

CellResearch Announces Global Clinical Results for PTT-6 at KALDAT Conference

Research Director Ivor Lim: "Significant improvement in US Phase 1 clinical trials for diabetic foot ulcers; preparing for Phase 2" Also developing treatment platforms for neurodegenerative diseases, arthritis, SLE, gene deficiency diseases, and targeted cancer therapy
CellResearch Research Director Ivor Lim presenting global clinical results for the super exosome 'PTT-6' at the KALDAT International Conference.
The era of next-generation super exosomes has fully opened, overcoming the limitations of exosomes with application possibilities transcending skin, hair loss, and wound regeneration.
On the 11th, stem cell-based bio-specialist 'CellResearch' was invited to the '2025 Korean Academy of Laser, Dermatology and Trichology Spring International Academic Forum' (KALDAT), Korea's largest medical device and aesthetic conference held at COEX in Seoul. At the event, Co-founder and Research Director Dr. Ivor J. Lim presented key data on the mechanism of action of the next-generation super exosome technology ‘PTT-6,’ clinical results from over 40 countries worldwide, and wound regeneration effects.
PTT-6 is a Super Exosome independently developed by CellResearch with an R&D investment of approximately 50 billion KRW. It is a next-generation super exosome complex successfully commercialized by extracting cell-free culture media from New Zealand red deer umbilical cord lining-derived stem cells. Unlike single extract components, it features a concentration of over 3,000 bioactive factors (exosomes, growth factors, microRNAs, anti-inflammatory cytokines, etc.) in an optimal ratio, simultaneously inducing various physiological reactions such as tissue regeneration, inflammation regulation, angiogenesis, and collagen remodeling.
CellResearch Announces Global Clinical Results for PTT-6 at KALDAT Conference

"Significant Effects in 8 out of 10 Patients, Some with Dramatic Changes"... Clinical Results of Hair Loss Treatment Revealed

"Changing the scalp environment first"... PTT-6 based 'CALECIM' effective even for intractable hair loss PTT-6 and RF combination therapy reduces pain and maximizes hair loss improvement effects
Professor Kim Ji-seok of the Asian Association of FUE Hair Transplant Surgeons (FUE ASIA) and Director of Mammoth Hairline Clinic announced at the '2025 Korean Academy of Laser, Dermatology and Trichology' (KALDAT) international conference, held at COEX in Seoul on the 11th, that domestic clinical trials of the stem cell super-exosome based 'CALECIM' showed improvement effects in 8 out of 10 hair loss patients, with some exhibiting dramatic changes.
According to CellResearch, 'CALECIM,' a hair loss and skin regeneration solution based on the super-exosome 'PTT-6,' is a product reported to increase dermal papilla cell proliferation by 24%, reduce scalp inflammation by 30-fold, increase the number of active follicles by 15%, and improve total hair count by 14% with standalone use alone. It has been introduced in approximately 4,500 hospitals and clinics across more than 40 countries worldwide.
Director Kim Ji-seok emphasized, "In the pilot clinical trial using CALECIM, we confirmed significant clinical responses in intractable hair loss patients through a new treatment mechanism different from existing methods." He added, "It demonstrated new possibilities for hair loss treatment in patients unresponsive to existing therapies, and we expect the paradigm of hair loss treatment to shift significantly in the future."
This clinical trial was conducted on 10 hair loss patients (5 males, 5 females, average age 40). The procedure involved a combination of Radio Frequency (RF) treatment and the PTT-6 complex. Each patient received applications of PTT-6 (2.5ml–5ml) following RF laser treatment three times at one-month intervals, and progress was observed for approximately two months after the procedures. As a result, visible improvement responses appeared in 8 patients, and among them, significant changes were confirmed, including an increase of over 10% in hair diameter and follicle density.
"Significant Effects in 8 out of 10 Patients, Some with Dramatic Changes"... Clinical Results of Hair Loss Treatment Revealed

CellResearch Unveils Stem Cell Technology in Korea for the First Time

CellResearch Research Director Ivor Lim presenting at the '2024 Asia-Pacific Anti-Aging Conference'. Photo provided by CellResearch
Dr. Ivor J. Lim, Chief Scientific Officer (CSO) of CellResearch, unveiled the company’s umbilical cord lining stem cell technology for the first time in Korea through a main keynote address at the '2024 Asia-Pacific Anti-Aging Conference' (APAAC 2024) held at EXCO in Daegu.
Research Director Ivor Lim is the co-founder and CSO of CellResearch. After graduating from the University of Cambridge School of Clinical Medicine (MA, MB BChir), he practiced in the UK and Singapore. He has won numerous awards in Europe and Asia, including the Ian McGregor Gold Medal from the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS), the highest authority in Europe.
During the dinner keynote lecture—the highlight of APAAC—on November 30th, Director Lim revealed for the first time in Korea the world's first umbilical cord lining stem cell 'PTT-6' developed by CellResearch, the core technology of the commercialized stem cell hair loss solution 'CALECIM,' and global clinical results. The presentation drew significant attention from conference participants.
'PTT-6' utilizes 'Umbilical Cord Lining,' a stem cell source newly discovered by CellResearch. Through proprietary technology, the company succeeded in commercializing the extraction and culture of 99% ultra-high purity and high-content stem cells. It is an effective active ingredient with vastly superior purity, content, and composition compared to existing stem cell sources.
CellResearch Unveils Stem Cell Technology in Korea for the First Time

CellResearch Super Exosome ‘PTT-6’ Lands in Korea... Caring for Hair Loss, Skin, and Wound Regeneration

Superior purity, content, and composition compared to existing stem cell sources... Optimal extraction purity and yield ‘Large-scale Clinical Campaign’ for medical staff to be held at the conference... ‘CALECIM’ also unveiled for the first time
The next-generation super exosome 'PTT-6,' which has overcome the limitations of existing exosomes through an R&D investment of approximately 50 billion KRW, is officially launching in Korea.
On the 7th, stem cell-based bio-specialist 'CellResearch' announced that it has been invited to the '2025 Korean Academy of Laser, Dermatology and Trichology Spring International Academic Forum' (KALDAT), Korea's largest medical device and aesthetic conference to be held at COEX in Seoul on the 11th. There, the company will present clinical results for the Super Exosome 'PTT-6,' which is capable of caring for hair loss, skin regeneration, and even intractable chronic wounds.
CellResearch also plans to unveil 'CALECIM,' a hair loss and skin regeneration solution based on PTT-6, for the first time.
CellResearch Corp is a world-class stem cell platform company headquartered in Singapore. It has invested a total of approximately 50 billion KRW in research and development—including about 11 billion KRW supported by the Singapore National Research Foundation (NRF) and the National Neuroscience Institute (NNI)—to successfully develop the next-generation super exosome 'PTT-6,' possessing unrivaled technology in the stem cell field. It has secured intellectual property rights by completing core patent registrations in 70 countries worldwide. The company is currently pursuing a NASDAQ listing, with a corporate value reaching approximately 1 trillion KRW. Domestic supply is handled by 'Keynstone.'
CellResearch Super Exosome ‘PTT-6’ Lands in Korea... Caring for Hair Loss, Skin, and Wound Regeneration